Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alberto Floris

Showing results (51-60 of 67) with videos related to

Pageof 7
Sort By:
Clinical and Experimental Rheumatology|July 25, 2024
Effectiveness of ixekizumab over 24 months in different clinical scenarios in psoriatic arthritis: results from the Gruppo Italiano Studio Early Arthritis multicentric prospective registryMaria Sole Chimenti, Mauro Fatica, Marco Fornaro, et al.
RMD Open|July 25, 2020
Development and preliminary validation of the Behçet's syndrome Overall Damage Index (BODI)Matteo Piga, Alberto Floris, Gerard Espinosa, et al.
Rheumatology (Oxford, England)|December 17, 2019
Risk factors of damage in early diagnosed systemic lupus erythematosus: results of the Italian multicentre Early Lupus Project inception cohortMatteo Piga, Alberto Floris, Gian Domenico Sebastiani, et al.
RMD Open|December 29, 2022
Glucocorticoid tapering and associated outcome in patients with newly diagnosed systemic lupus erythematosus: the real-world GULP prospective observational studyAlberto Floris, Elisabetta Chessa, Gian Domenico Sebastiani, et al.
Rheumatology (Oxford, England)|April 18, 2026
Phenotypic differences and treatment persistence in a large multicenter cohort of axial psoriatic arthritisGiuseppe Lopalco, Sergio Del Vescovo, Michele Maria Luchetti, et al.
Annals of the Rheumatic Diseases|October 17, 2024
Efficacy and safety of infliximab or adalimumab in severe mucocutaneous Behçet's syndrome refractory to traditional immunosuppressants: a 6-month, multicentre, randomised controlled, prospective, parallel group, single-blind trialRosaria Talarico, Nazzareno Italiano, Giacomo Emmi, et al.
The Journal of Rheumatology|June 17, 2018
Physician's Global Assessment in Psoriatic Arthritis: A Multicenter GRAPPA StudyAlberto Cauli, Dafna D Gladman, Alessandro Mathieu, et al.
Therapeutic Advances in Musculoskeletal Disease|September 16, 2021
Anakinra and canakinumab for patients with R92Q-associated autoinflammatory syndrome: a multicenter observational study from the AIDA NetworkCarla Gaggiano, Donato Rigante, José Hernández-Rodríguez, et al.
Therapeutic Advances in Musculoskeletal Disease|February 3, 2025
Efficacy and retention rate of secukinumab in psoriatic arthritis across different clinical phenotypes: insights from the Italian GISEA RegistryGiuseppe Lopalco, Maria Morrone, Fabiola Atzeni, et al.
Rheumatology (Oxford, England)|November 29, 2025
The impact of demographics on organ damage in Behçet's syndrome: a cross-sectional analysis of the international PROBE cohortAlberto Floris, Riccardo Laconi, Sarra Chadli, et al.
Pageof 7

Showing results (51-60 of 67) with videos related to

Sort By:
Pageof 7
Clinical and Experimental Rheumatology|July 25, 2024
Effectiveness of ixekizumab over 24 months in different clinical scenarios in psoriatic arthritis: results from the Gruppo Italiano Studio Early Arthritis multicentric prospective registryMaria Sole Chimenti, Mauro Fatica, Marco Fornaro, et al.
RMD Open|July 25, 2020
Development and preliminary validation of the Behçet's syndrome Overall Damage Index (BODI)Matteo Piga, Alberto Floris, Gerard Espinosa, et al.
Rheumatology (Oxford, England)|December 17, 2019
Risk factors of damage in early diagnosed systemic lupus erythematosus: results of the Italian multicentre Early Lupus Project inception cohortMatteo Piga, Alberto Floris, Gian Domenico Sebastiani, et al.
RMD Open|December 29, 2022
Glucocorticoid tapering and associated outcome in patients with newly diagnosed systemic lupus erythematosus: the real-world GULP prospective observational studyAlberto Floris, Elisabetta Chessa, Gian Domenico Sebastiani, et al.
Rheumatology (Oxford, England)|April 18, 2026
Phenotypic differences and treatment persistence in a large multicenter cohort of axial psoriatic arthritisGiuseppe Lopalco, Sergio Del Vescovo, Michele Maria Luchetti, et al.
Annals of the Rheumatic Diseases|October 17, 2024
Efficacy and safety of infliximab or adalimumab in severe mucocutaneous Behçet's syndrome refractory to traditional immunosuppressants: a 6-month, multicentre, randomised controlled, prospective, parallel group, single-blind trialRosaria Talarico, Nazzareno Italiano, Giacomo Emmi, et al.
The Journal of Rheumatology|June 17, 2018
Physician's Global Assessment in Psoriatic Arthritis: A Multicenter GRAPPA StudyAlberto Cauli, Dafna D Gladman, Alessandro Mathieu, et al.
Therapeutic Advances in Musculoskeletal Disease|September 16, 2021
Anakinra and canakinumab for patients with R92Q-associated autoinflammatory syndrome: a multicenter observational study from the AIDA NetworkCarla Gaggiano, Donato Rigante, José Hernández-Rodríguez, et al.
Therapeutic Advances in Musculoskeletal Disease|February 3, 2025
Efficacy and retention rate of secukinumab in psoriatic arthritis across different clinical phenotypes: insights from the Italian GISEA RegistryGiuseppe Lopalco, Maria Morrone, Fabiola Atzeni, et al.
Rheumatology (Oxford, England)|November 29, 2025
The impact of demographics on organ damage in Behçet's syndrome: a cross-sectional analysis of the international PROBE cohortAlberto Floris, Riccardo Laconi, Sarra Chadli, et al.
Pageof 7